Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Blake Nordblad"'
Autor:
Jennifer Lloyd, Blake Nordblad, Kamal Kant Kant Sahu, Umang Swami, Tenzin Kunsang Phunrab, Julia Anne Batten, Lindsay Maxwell, Manish Kohli, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal
Publikováno v:
Journal of Clinical Oncology. 41:105-105
105 Background: In clinical trials, treatment efficacy rates are based on participants who can tolerate treatment through study endpoints. Attrition from clinical trials can potentially lead to biased results (PMID: 30379822). Many oncology clinical
Autor:
Haoran Li, Kamal Kant Kant Sahu, Georges Gebrael, Beverly Chigarira, Vinay Mathew Thomas, Yeonjung Jo, Shruti Adidam Kumar, Blake Nordblad, James Brundage, Nishita Tripathi, Nicolas Sayegh, Umang Swami, Neeraj Agarwal, Benjamin L. Maughan
Publikováno v:
Journal of Clinical Oncology. 41:726-726
726 Background: VTE is a common complication in pts with mRCC. Identifying pts with mRCC at the highest risk of developing VTE may provide the rationale for initiating prophylactic anticoagulation. Methods: In this IRB-approved retrospective study, p
Autor:
Nishita Tripathi, Haoran Li, Yeonjung Jo, Nicolas Sayegh, Clara Tandar, Roberto Nussenzveig, Benjamin Haaland, Jackson Cheney, Divyam Goel, Blake Nordblad, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Publikováno v:
Journal of Clinical Oncology. 40:373-373
373 Background: Renal cell carcinoma is predominant in 6th to 8th decade of life. Younger pts are more likely to have symptomatic tumors on presentation but with favorable pathological features and disease specific survival (PMID: 17092632). Herein,
Autor:
Nicolas Sayegh, Nishita Tripathi, Taylor Ryan McFarland, Adam Kessel, Roberto Nussenzveig, Beverly Chigarira, Haoran Li, Clara Tandar, Divyam Goel, Blake Nordblad, Jackson Cheney, Kamal Kant Sahu, Benjamin L. Maughan, Umang Swami, Neeraj Agarwal
Publikováno v:
Journal of Clinical Oncology. 40:121-121
121 Background: Novel hormonal therapy (NHT) i.e. novel androgen receptor or androgen synthesis inhibitors have been approved for treatment of pts with mCSPC and mCRPC based on improved OS. However, OS of patients after progression on first-line NHT